Viral Vector-Mediated Antisense Therapy for Genetic Diseases

Overview

Journal Genes (Basel)

Publisher MDPI

Date 2017 Jan 31

PMID 28134780

Citations 10

Authors

Marine Imbert

Gabriella Dias-Florencio

Aurelie Goyenvalle

Affiliations

Soon will be listed here.

Abstract

RNA plays complex roles in normal health and disease and is becoming an important target for therapeutic intervention; accordingly, therapeutic strategies that modulate RNA function have gained great interest over the past decade. Antisense oligonucleotides (AOs) are perhaps the most promising strategy to modulate RNA expression through a variety of post binding events such as gene silencing through degradative or non-degradative mechanisms, or splicing modulation which has recently demonstrated promising results. However, AO technology still faces issues like poor cellular-uptake, low efficacy in target tissues and relatively rapid clearance from the circulation which means repeated injections are essential to complete therapeutic efficacy. To overcome these limitations, viral vectors encoding small nuclear RNAs have been engineered to shuttle antisense sequences into cells, allowing appropriate subcellular localization with pre-mRNAs and permanent correction. In this review, we outline the different strategies for antisense therapy mediated by viral vectors and provide examples of each approach. We also address the advantages and limitations of viral vector use, with an emphasis on their clinical application.

Citing Articles

Development of Engineered-U1 snRNA Therapies: Current Status.

Goncalves M, Santos J, Coutinho M, Matos L, Alves S Int J Mol Sci. 2023; 24(19).

PMID: 37834063 PMC: 10572768. DOI: 10.3390/ijms241914617.

Programmable macromolecule-based RNA-targeting therapies to treat human neurological disorders.

Morelli K, Smargon A, Yeo G RNA. 2023; 29(4):489-497.

PMID: 36693761 PMC: 10019361. DOI: 10.1261/rna.079519.122.

Noncoding RNA therapeutics for substance use disorder.

Seyednejad S, Sartor G Adv Drug Alcohol Res. 2023; 2.

PMID: 36601439 PMC: 9808746. DOI: 10.3389/adar.2022.10807.

Antisense Oligonucleotide Therapy for the Nervous System: From Bench to Bedside with Emphasis on Pediatric Neurology.

Amanat M, Nemeth C, Smith Fine A, Leung D, Fatemi A Pharmaceutics. 2022; 14(11).

PMID: 36365206 PMC: 9695718. DOI: 10.3390/pharmaceutics14112389.

From Antisense RNA to RNA Modification: Therapeutic Potential of RNA-Based Technologies.

Adachi H, Hengesbach M, Yu Y, Morais P Biomedicines. 2021; 9(5).

PMID: 34068948 PMC: 8156014. DOI: 10.3390/biomedicines9050550.

References

Goyenvalle A, Wright J, Babbs A, Wilkins V, Garcia L, Davies K . Engineering multiple U7snRNA constructs to induce single and multiexon-skipping for Duchenne muscular dystrophy. Mol Ther. 2012; 20(6):1212-21. PMC: 3369406. DOI: 10.1038/mt.2012.26. View

Gorman L, Suter D, Emerick V, Schumperli D, Kole R . Stable alteration of pre-mRNA splicing patterns by modified U7 small nuclear RNAs. Proc Natl Acad Sci U S A. 1998; 95(9):4929-34. PMC: 20190. DOI: 10.1073/pnas.95.9.4929. View

Hua Y, Vickers T, Okunola H, Bennett C, Krainer A . Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am J Hum Genet. 2008; 82(4):834-48. PMC: 2427210. DOI: 10.1016/j.ajhg.2008.01.014. View

Miller J, Urbinati C, Stenberg M, Byrne B, Thornton C, Swanson M . Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy. EMBO J. 2000; 19(17):4439-48. PMC: 302046. DOI: 10.1093/emboj/19.17.4439. View

Koenig M, Beggs A, Moyer M, Scherpf S, Heindrich K, Bettecken T . The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet. 1989; 45(4):498-506. PMC: 1683519. View

Porensky P, Mitrpant C, McGovern V, Bevan A, Foust K, Kaspar B . A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse. Hum Mol Genet. 2011; 21(7):1625-38. PMC: 3298284. DOI: 10.1093/hmg/ddr600. View

Schumperli D, Pillai R . The special Sm core structure of the U7 snRNP: far-reaching significance of a small nuclear ribonucleoprotein. Cell Mol Life Sci. 2004; 61(19-20):2560-70. DOI: 10.1007/s00018-004-4190-0. View

Goyenvalle A, Babbs A, Wright J, Wilkins V, Powell D, Garcia L . Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping. Hum Mol Genet. 2012; 21(11):2559-71. PMC: 3349427. DOI: 10.1093/hmg/dds082. View

Davis B, McCurrach M, TANEJA K, Singer R, Housman D . Expansion of a CUG trinucleotide repeat in the 3' untranslated region of myotonic dystrophy protein kinase transcripts results in nuclear retention of transcripts. Proc Natl Acad Sci U S A. 1997; 94(14):7388-93. PMC: 23831. DOI: 10.1073/pnas.94.14.7388. View

10.

Vulin A, Barthelemy I, Goyenvalle A, Thibaud J, Beley C, Griffith G . Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping. Mol Ther. 2012; 20(11):2120-33. PMC: 3498802. DOI: 10.1038/mt.2012.181. View

11.

Hua Y, Liu Y, Sahashi K, Rigo F, Bennett C, Krainer A . Motor neuron cell-nonautonomous rescue of spinal muscular atrophy phenotypes in mild and severe transgenic mouse models. Genes Dev. 2015; 29(3):288-97. PMC: 4318145. DOI: 10.1101/gad.256644.114. View

12.

Dickson A, Osman E, Lorson C . A negatively acting bifunctional RNA increases survival motor neuron both in vitro and in vivo. Hum Gene Ther. 2009; 19(11):1307-15. PMC: 2940461. DOI: 10.1089/hum.2008.067. View

13.

Gorman L, Mercatante D, Kole R . Restoration of correct splicing of thalassemic beta-globin pre-mRNA by modified U1 snRNAs. J Biol Chem. 2000; 275(46):35914-9. DOI: 10.1074/jbc.M006259200. View

14.

Gaudet D, Methot J, Dery S, Brisson D, Essiembre C, Tremblay G . Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther. 2012; 20(4):361-9. PMC: 4956470. DOI: 10.1038/gt.2012.43. View

15.

Neri M, Torelli S, Brown S, Ugo I, Sabatelli P, Merlini L . Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human. Neuromuscul Disord. 2007; 17(11-12):913-8. DOI: 10.1016/j.nmd.2007.07.005. View

16.

Garber K . Big win possible for Ionis/Biogen antisense drug in muscular atrophy. Nat Biotechnol. 2016; 34(10):1002-1003. DOI: 10.1038/nbt1016-1002. View

17.

Voit T, Topaloglu H, Straub V, Muntoni F, Deconinck N, Campion G . Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol. 2014; 13(10):987-96. DOI: 10.1016/S1474-4422(14)70195-4. View

18.

Cartegni L, Krainer A . Correction of disease-associated exon skipping by synthetic exon-specific activators. Nat Struct Biol. 2003; 10(2):120-5. DOI: 10.1038/nsb887. View

19.

Goyenvalle A, Babbs A, van Ommen G, Garcia L, Davies K . Enhanced exon-skipping induced by U7 snRNA carrying a splicing silencer sequence: Promising tool for DMD therapy. Mol Ther. 2009; 17(7):1234-40. PMC: 2835201. DOI: 10.1038/mt.2009.113. View

20.

Liu S, Asparuhova M, Brondani V, Ziekau I, Klimkait T, Schumperli D . Inhibition of HIV-1 multiplication by antisense U7 snRNAs and siRNAs targeting cyclophilin A. Nucleic Acids Res. 2004; 32(12):3752-9. PMC: 484190. DOI: 10.1093/nar/gkh715. View